Tag: dermatitis

UV Light Linked to Prevention of Allergic Disease in Infants

Higher direct ultraviolet (UV) light exposure in the first 3 months of life was linked to lower incidence of proinflammatory immune markers and lower incidence...

Dupilumab Safe, Effective in Kids With Moderate-to-Severe Asthma

Dupilumab (Dupixent, Sanofi and Regeneron) significantly reduced exacerbations compared with placebo in children ages 6-11 years who had moderate-to-severe asthma in a phase 3 trial....

Expert Shares Practical Considerations for Dupilumab Treatment

Clinicians who struggle to get dupilumab approved for their patients with moderate to severe atopic dermatitis (AD) are not alone. This scenario was illustrated in...

Topical Ruxolitinib Found Safe, Effective in 52-Week AD Study

After treatment with ruxolitinib cream for 52 weeks, between 60% and 80% of atopic dermatitis patients maintained clear or almost clear skin, with no safety...

Study Estimates Incidence of Dupilumab-Related Conjunctivitis

One in 15 patients who start dupilumab treatment may develop conjunctivitis during the first 6 months, most of which is manageable with ophthalmic treatments, results...

Emollient Data Discouraging for Atopic Dermatitis Prevention

Emollients don’t prevent atopic dermatitis (AD), but they might have untapped potential as treatment, two new studies suggest. The results of a prevention study, in...

Study Finds Psoriasis Associated With an Increased COVID-19 Risk

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. People with psoriasis have a higher risk of infection with COVID-19...

Multidisciplinary Approach Touted for Atopic Dermatitis

Bringing pharmacists, allergists, and dermatologists together to discuss patient care can improve outcomes for children with atopic dermatitis, researchers say. “I think we really gained...

Novel S1P-Receptor Modulator Shows Promise in Phase 2b AD Trial

A novel, highly selective oral sphingosine 1-phosphate (S1P)–receptor modulator showed promise as a treatment for atopic dermatitis (AD) in a 12-week phase 2b trial, according...

Tralokinumab Gets Nod for Atopic Dermatitis in Europe

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the IL-13 inhibitor...

Study Enhances Understanding of Prurigo Nodularis

Patients with prurigo nodularis tend to make a greater number of visits to health care specialists and are burdened by a greater number of medical...

The Tick Talk for Families and Pediatricians

Spring 2021 has arrived with summer quickly approaching. It is our second spring and summer during the pandemic. Travel restrictions have minimally eased for vaccinated...

Expert Highlights Advances in DRESS

Mounting evidence suggests it’s a mistake to reject the diagnosis of drug reaction with eosinophilia and systemic symptoms, or DRESS, simply because the interval between...

FDA OKs First Injectable Complete Drug Regimen for HIV

The US Food and Drug Administration (FDA) has approved Cabenuva, an injectable formulation of cabotegravir (Vocabria) and rilpivirine (Edurant), for adults living with HIV-1 infection....

Curbing Itch Intensity, Frequency in Children With Severe Eczema

Dupilumab treatment with concomitant topical corticosteroids provided rapid and sustained improvement in itch intensity and frequency in children aged 6-11 years with severe atopic dermatitis....

Study Finds AD Significantly Associated With Autoimmune Diseases

A diagnosis of atopic dermatitis in individuals ages 15 years or older, compared with controls without atopic dermatitis, was nearly twice as likely to be...

Gene Expression Different in Allergic, Irritant Contact Dermatitis

NEW YORK (Reuters Health) – Artificial intelligence (AI) can help identify biomarkers to distinguish between contact dermatitis (CD) due to allergic reactions or to irritants,...

COVID-19 Appeared in Italy in November 2019, Study Shows

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Retroactive testing shows COVID-19 appeared in Italy about three months earlier...

Beta-Blocker May Improve Melanoma Treatment Response

Response rates were high without dose-limiting toxicities in a small phase 1 study that evaluated the addition of propranolol to pembrolizumab in treatment-naive patients with...

Improvements in Chronic Hand Eczema Seen With Oral Gusacitinib

Gusacitinib, a novel oral inhibitor of multiple inflammatory pathways, achieved rapid and clinically meaningful improvement in corticosteroid-refractory moderate to severe chronic hand eczema in a...

Topical Tapinarof Effective in Pivotal Psoriasis Trials

Tapinarof cream 1% applied once daily in patients with plaque psoriasis convincingly hit its primary and secondary endpoints and was well tolerated in two identical...

Delgocitinib Successful for Hand Eczema in Phase 2b Trial

Delgocitinib cream shows a dose-dependent response in easing chronic hand eczema, a common and difficult-to-treat disorder for which few other topical options are available, new...

How to Relieve One of the Itchiest Vulvar Conditions

A three-step approach may help relieve itch in patients with lichen simplex chronicus, “one of the itchiest conditions that we ever see on the vulva,”...

Tailoring Treatment for Psoriasis, PsA, and Pregnancy

With an average age of diagnosis of 28 years, and one of two incidence peaks occurring at 15-30 years, psoriasis affects many women in the...

COVID-19 Update: Conspiracy Theories, Cutaneous Clues

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Here are the coronavirus stories Medscape’s editors around the globe think...